Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis

BACKGROUND: Rifaximin therapy reduced risk of hepatic encephalopathy (HE) recurrence and HE-related hospitalisations during a 6-month, randomised, placebo-controlled trial (RCT) and a 24-month open-label maintenance (OLM) study. However, the impact of crossover from placebo to rifaximin therapy is u...

Descripción completa

Detalles Bibliográficos
Autores principales: Bajaj, J S, Barrett, A C, Bortey, E, Paterson, C, Forbes, W P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Ltd 2015
Materias:
Rifaximin for Hepatic Encephalopathy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284039/
https://www.ncbi.nlm.nih.gov/pubmed/25339518
http://dx.doi.org/10.1111/apt.12993

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284039/
https://www.ncbi.nlm.nih.gov/pubmed/25339518
http://dx.doi.org/10.1111/apt.12993

Ejemplares similares